PT923530E - Inibicao de metaloproteases de matriz por acidos biaril oxibutiricos substituidos - Google Patents
Inibicao de metaloproteases de matriz por acidos biaril oxibutiricos substituidosInfo
- Publication number
- PT923530E PT923530E PT97926455T PT97926455T PT923530E PT 923530 E PT923530 E PT 923530E PT 97926455 T PT97926455 T PT 97926455T PT 97926455 T PT97926455 T PT 97926455T PT 923530 E PT923530 E PT 923530E
- Authority
- PT
- Portugal
- Prior art keywords
- oxibutiary
- biaril
- inhibition
- acids
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/04—1,2,3-Triazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64849396A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT923530E true PT923530E (pt) | 2004-12-31 |
Family
ID=24601014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97926455T PT923530E (pt) | 1996-05-15 | 1997-05-12 | Inibicao de metaloproteases de matriz por acidos biaril oxibutiricos substituidos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0923530B1 (pt) |
| JP (1) | JP3354942B2 (pt) |
| CN (1) | CN1100748C (pt) |
| AR (1) | AR007098A1 (pt) |
| AT (1) | ATE275123T1 (pt) |
| AU (1) | AU714207B2 (pt) |
| BR (1) | BR9709086A (pt) |
| CA (1) | CA2254731C (pt) |
| CO (1) | CO5011061A1 (pt) |
| DE (1) | DE69730508T2 (pt) |
| DK (1) | DK0923530T3 (pt) |
| ES (1) | ES2227696T3 (pt) |
| HK (1) | HK1021897A1 (pt) |
| HR (1) | HRP970244B1 (pt) |
| ID (1) | ID17291A (pt) |
| MY (1) | MY132463A (pt) |
| PA (1) | PA8429701A1 (pt) |
| PE (1) | PE66898A1 (pt) |
| PT (1) | PT923530E (pt) |
| SV (1) | SV1997000036A (pt) |
| TN (1) | TNSN97083A1 (pt) |
| TW (1) | TW539672B (pt) |
| WO (1) | WO1997043239A1 (pt) |
| YU (1) | YU18597A (pt) |
| ZA (1) | ZA974030B (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925637A (en) * | 1997-05-15 | 1999-07-20 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids |
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| GB9922710D0 (en) * | 1999-09-24 | 1999-11-24 | Bayer Ag | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatatives for the treatment of multiple sclerosis |
| PA8539401A1 (es) * | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| JP2004359546A (ja) * | 2001-03-15 | 2004-12-24 | Ono Pharmaceut Co Ltd | ヒドロキサム酸誘導体、それらの非毒性塩およびそれらのプロドラッグ体を有効成分として含有する、固形癌の予防および／または治療剤 |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| KR101405823B1 (ko) * | 2007-12-24 | 2014-06-12 | 주식회사 케이티앤지생명과학 | 녹내장의 치료 및 예방을 위한 약제 조성물 |
| KR20090071829A (ko) * | 2007-12-28 | 2009-07-02 | 주식회사 머젠스 | 신장질환의 치료 및 예방을 위한 약제 조성물 |
| WO2010021693A2 (en) * | 2008-08-18 | 2010-02-25 | Yale University | Mif modulators |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| WO2015150363A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| WO2015150350A1 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren zur behandlung von atemwegserkrankungen |
| WO2015150362A2 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
| CN113979992B (zh) * | 2021-11-19 | 2022-06-24 | 西安欧得光电材料有限公司 | 一种3-取代二苯并噻吩及其合成方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0905126B1 (en) * | 1994-01-22 | 2002-12-04 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1997
- 1997-05-09 MY MYPI97002043A patent/MY132463A/en unknown
- 1997-05-09 TN TNTNSN97083A patent/TNSN97083A1/fr unknown
- 1997-05-09 ZA ZA9704030A patent/ZA974030B/xx unknown
- 1997-05-09 HR HR970244A patent/HRP970244B1/xx not_active IP Right Cessation
- 1997-05-09 CO CO97025174A patent/CO5011061A1/es unknown
- 1997-05-12 BR BR9709086A patent/BR9709086A/pt not_active Application Discontinuation
- 1997-05-12 JP JP54100397A patent/JP3354942B2/ja not_active Expired - Fee Related
- 1997-05-12 PT PT97926455T patent/PT923530E/pt unknown
- 1997-05-12 TW TW086106285A patent/TW539672B/zh not_active IP Right Cessation
- 1997-05-12 CN CN97196454A patent/CN1100748C/zh not_active Expired - Fee Related
- 1997-05-12 AR ARP970101978A patent/AR007098A1/es unknown
- 1997-05-12 DK DK97926455T patent/DK0923530T3/da active
- 1997-05-12 YU YU18597A patent/YU18597A/sh unknown
- 1997-05-12 PA PA19978429701A patent/PA8429701A1/es unknown
- 1997-05-12 AT AT97926455T patent/ATE275123T1/de not_active IP Right Cessation
- 1997-05-12 DE DE69730508T patent/DE69730508T2/de not_active Expired - Fee Related
- 1997-05-12 PE PE1997000365A patent/PE66898A1/es not_active Application Discontinuation
- 1997-05-12 ES ES97926455T patent/ES2227696T3/es not_active Expired - Lifetime
- 1997-05-12 SV SV1997000036A patent/SV1997000036A/es not_active Application Discontinuation
- 1997-05-12 EP EP97926455A patent/EP0923530B1/en not_active Expired - Lifetime
- 1997-05-12 WO PCT/US1997/007976 patent/WO1997043239A1/en active IP Right Grant
- 1997-05-12 AU AU31220/97A patent/AU714207B2/en not_active Ceased
- 1997-05-12 CA CA002254731A patent/CA2254731C/en not_active Expired - Fee Related
- 1997-05-14 ID IDP971611A patent/ID17291A/id unknown
-
2000
- 2000-02-10 HK HK00100770A patent/HK1021897A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1021897A1 (en) | 2000-07-14 |
| JP3354942B2 (ja) | 2002-12-09 |
| PA8429701A1 (es) | 2000-05-24 |
| DK0923530T3 (da) | 2005-01-03 |
| DE69730508D1 (de) | 2004-10-07 |
| EP0923530B1 (en) | 2004-09-01 |
| EP0923530A1 (en) | 1999-06-23 |
| ID17291A (id) | 1997-12-18 |
| CA2254731A1 (en) | 1997-11-20 |
| AR007098A1 (es) | 1999-10-13 |
| SV1997000036A (es) | 1998-07-20 |
| CN1100748C (zh) | 2003-02-05 |
| HRP970244A2 (en) | 1998-04-30 |
| TW539672B (en) | 2003-07-01 |
| ATE275123T1 (de) | 2004-09-15 |
| CA2254731C (en) | 2004-07-20 |
| HRP970244B1 (en) | 2005-06-30 |
| JPH11510821A (ja) | 1999-09-21 |
| ZA974030B (en) | 1998-02-19 |
| BR9709086A (pt) | 1999-08-03 |
| WO1997043239A1 (en) | 1997-11-20 |
| CN1225621A (zh) | 1999-08-11 |
| DE69730508T2 (de) | 2005-09-29 |
| TNSN97083A1 (fr) | 2005-03-15 |
| AU3122097A (en) | 1997-12-05 |
| YU18597A (sh) | 2001-12-26 |
| PE66898A1 (es) | 1998-10-22 |
| AU714207B2 (en) | 1999-12-23 |
| CO5011061A1 (es) | 2001-02-28 |
| ES2227696T3 (es) | 2005-04-01 |
| MY132463A (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200000573A (et) | Asendatud indoolalkaanhapped | |
| BR9609989A (pt) | Compostos de benzilaminopiperidina substituídos | |
| MA26500A1 (fr) | Forme nouvelle de s-omerprazole | |
| BR9403948A (pt) | Composição de matéria | |
| BR9403946A (pt) | Composição de matéria | |
| BR9509200A (pt) | Composição de matéria | |
| BR9711223A (pt) | Derivados de cido arilsulfonilamino-hidrox mico | |
| DK0877018T3 (da) | Sulfonylaminocarboxylsyrer | |
| PT923530E (pt) | Inibicao de metaloproteases de matriz por acidos biaril oxibutiricos substituidos | |
| ID17792A (id) | Penghambat penghambat metaloproreinase matriks | |
| FI974493A0 (fi) | Arrangemang i samband med en hydraulisk slaganordning | |
| PT907632E (pt) | Inibicao de metaloproteases de matriz por compostos fenetilo substituidos | |
| ID16838A (id) | Komposisi dekafluoropentana | |
| NO20001777L (no) | Fremgangsmate for fremstilling av substituerte 4-fenyl-4-cyanocykloheksankarboksylsyrer | |
| FI952707A0 (fi) | Syöttöveden esilämmitinjärjestelmä | |
| ID20291A (id) | Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa | |
| HRP970242A2 (en) | Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutric acids | |
| BR9610139A (pt) | Derivado de ácido carboxílico | |
| ATE183114T1 (de) | Feste zusammensetzung | |
| ID17419A (id) | Komposisi dekafluoropentana | |
| DE59407087D1 (de) | Formzylinder | |
| KR950000321U (ko) | 이불 | |
| BR9704770A (pt) | Derivados de 1-carba-(detia)-cefalosporina | |
| KR960028214U (ko) | 이불 | |
| ES1034319Y (es) | Juego de objetivos por grupos. |